<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00179413</url>
  </required_header>
  <id_info>
    <org_study_id>2001-P-000002</org_study_id>
    <nct_id>NCT00179413</nct_id>
  </id_info>
  <brief_title>Study of Long-Term Peg Intron Vs. Colchicine in Non-Responders.</brief_title>
  <official_title>Phase IV Study of Long Term Peg-Intron for Patients Who Have Failed to Respond to Rebetron/Interferon With Advanced Fibrosis and Cirrhosis Secondary to Hepatitis C- The Copilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Schering-Plough</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study Peg-Intron will be tested to see if it will give better results than
      Colchicine. At this time, there is currently no recommended maintenance treatment for
      patients who have failed to respond to Interferon/Rebetron/Peg Intron and have advanced
      fibrosis. The purpose of this study is to compare two treatments to slow down the
      progression of liver disease and to prevent liver failure and liver cancer. The treatment
      will not cure Hepatitis C, but is being evaluated to see if it can slow down disease
      progression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We are proposing a randomized trial of Peg-Intron 0.5mcg per kg weekly versus colchicine
      0.6mg bid in prior non-responders to Interferon, Rebetron, PegIntron, or PegIntron &amp;
      Ribavirin or any third agent such as Pegasys, CellCept, Amantadine with advanced
      fibrosis/cirrhosis. The specific aims of this proposal are to evaluate the role of long term
      Peg-Intron therapy on the natural history of patients with advanced chronic HCV infection
      with a primary focus on prevention of hepatic decompensation, progression of fibrosis and
      hepatoma development.

      The study design will focus on 3 monthly clinical evaluation for decompensation of liver
      function, rigorous clinical screening for development of hepatocellular cancer and liver
      biopsies for determination of progression of liver fibrosis every second year.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2001</start_date>
  <completion_date>December 2009</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Determination of the effect of PEG-Intron 0.5mg per kg weekly sc versus colchicine 0.6mg bid daily on:</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>4 year survival or hepatic transplantation</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Variceal or portal hypertensive bleeding</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Development of jaundice, ascites or encephalopathy with an increase in CPT of &gt; 2 points</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Development of hepatoma</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of safety and tolerability of long term maintenance PEG-Intron in patients with cirrhosis</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the effect of long term maintenance PEG-Intron on quality of life</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of surrogate markers of fibrosis in determining effect of long term maintenance PEG-Intron on prevention of progression of fibrosis and correlation of fibrosis markers with pathology.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of portal hypertension</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression of histological fibrosis</measure>
  </secondary_outcome>
  <enrollment>800</enrollment>
  <condition>Hepatitis C Virus</condition>
  <condition>Advanced Fibrosis</condition>
  <condition>Cirrhosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG interferon Alfa-2b; Colchicine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  *Adult male or female, age 18 to 75 years

               -  HCV RNA positive by PCR

               -  Previous treatment with at least three months of interferon or interferon /
                  Ribavirin. Patients should have had no interferon for at least 2 months prior to
                  enrollment.

                    1. Non-responders are identified by failure to clear virus by PCR after a
                       minimum 3-month course of treatment and who have been off treatment for at
                       least 2 months with a positive PCR for HCV prior to entry into the current
                       study, 2) Partial responders have a reduction of 1 long in HCV RNA, but the
                       virus is still detectable, 3) Breakthrough patients have been negative on
                       treatment, but virus appeared while still on treatment, 4) Relapsers are
                       defined as negative PCR at some point during treatment, but virus
                       reoccurred or was detectable by HCV PCR when treatment stopped.

        Patients should have had a liver biopsy showing at least Stage 3 disease prior to being
        considered for this study. A baseline liver biopsy is necessary for inclusion in the
        study. Baseline liver biopsies can be performed within six months of entering the study.

        In patients with cirrhosis and endoscopic evidence of portal hypertension, a biopsy within
        the last 2 years is acceptable as the baseline biopsy. For patients with established
        cirrhosis on liver biopsy and no portal hypertension, a biopsy within 12 months can be
        used as the baseline biopsy if it is available for evaluation by the Pathology core. All
        these patients will still require liver biopsy at 2 years and 4 years. The decision to
        biopsy at 2 and 4 years is also a clinical decision and in the presence of clinical
        progression or coagulopathy, or where there may be a risk from liver biopsy, the
        Investigator should call the PI, Dr. Afdhal for a waiver of biopsy. Patients with Ishak
        Stage 3 and 4 require a biopsy within 6 months of randomization.

          -  Hemoglobin &gt;= 11 g/dl in males and 10 g/dl in females

          -  Neutrophil count &gt; 1,500/mm3

          -  Platelets &gt; 50, 000/mm3

        Platelet count: For standard dose of PEG-Intron 0.5mcg/kg platelet count must be greater
        than 70,000. Patients with platelet count 50 - 70,000 can start at 0.25mcg/kg for weeks 0
        - 4. If platelets fall to less than 30,000, stop treatment. If platelets remain &gt; 50,000
        at week 4, PEG-Intron can be increased to 0.5mcg/kg. Patients randomized to Colchicine
        with platelets 50,000 - 70,000 can be started at standard dose 0.6mg bid po with standard
        dose reduction.

          -  Prothrombin time &lt;= 3secs prolonged compared to control or an equivalent INR &lt; 1.5

          -  Total bilirubin &lt; 3gm/dL

          -  Fasting blood sugar &lt;= 115 mg/dl or within 20% of the upper limit of normal for
             non-diabetic patients

          -  Albumin (&gt; 2.8mg/dl)

          -  Serum creatinine &lt; 1.4 mg/dL

          -  TSH within the normal range (Patients with thyroid disease who are well controlled
             are eligible if the remainder of the inclusion/exclusion criteria are met)

          -  HIV negative.

               -  HBsAg negative

               -  Childs Pugh score of less than or equal to 7

               -  Serum positive for anti-hepatitis C antibodies or HCV RNA.

               -  Alpha-fetoprotein &lt; 100ng/ml with ultrasound negative for focal mass or HCC. For
                  any patient with an Alpha-fetoprotein &gt;100 ng/ml either a triple phase contrast
                  CT scan or MRI with gadolinium must show no focal mass or evidence of HCC

               -  Ultrasound with no evidence of focal mass suggestive of hepatoma (within 6
                  months of informed consent).

               -  Documentation that sexually active female patients of childbearing potential are
                  practicing adequate contraception during the treatment period. A urine pregnancy
                  test obtained at entry prior to the initiation of treatment must be negative.
                  Female patients must not be breast-feeding. Documentation that sexually active
                  male patients are practicing acceptable methods of contraception during the
                  treatment period.

               -  Written informed consent specific for this protocol has been obtained prior to
                  entry.

        Exclusion Criteria:

          -  Any cause of liver disease based on patient history and biopsy (where applicable)
             other than chronic hepatitis C including but not limited to:

               -  Co-infection with hepatitis B or HIV

               -  Hemochromatosis (confirmed by genetic testing)

               -  Alpha-1 antitrypsin deficiency

               -  Wilson's disease

               -  Renal or liver transplant patients

               -  Autoimmune hepatitis

               -  Alcoholic liver disease

               -  Obesity induced liver disease

               -  Drug related liver disease

        In addition:

          -  Evidence of decompensated liver disease such as a history or presence of ascites, and
             spontaneous encephalopathy. Patients with past bleeding esophageal varices that have
             not bled for more than 1 year can be included.

          -  Hypersensitivity to alpha interferon

          -  Drug related liver disease

          -  Hemoglobinopathies (e.g. Thalassaemia, sickle cell disease).

          -  Patients with clinically significant retinal abnormalities.

          -  Substance abuse, such as alcohol (Â·&gt; 80 gm/day), I.V. drugs and inhaled drugs. If the
             patient has a history of substance abuse, to be considered for inclusion into the
             protocol, the patient must have abstained from using the abused substance for at
             least 6 months. Patients on methadone will be allowed in the study with no
             restrictions as is now standard of care in HCV therapy.

          -  Patients with a history of organ transplantation will be excluded.

        Preexisting psychiatric conditions, especially depression, or a history of severe
        psychiatric disorder, such as major psychoses, suicidal ideation and/or suicidal attempt
        are excluded. Patients with a history of mild depression may enter the protocol if they
        meet the following eligibility criterion and are monitored more intensively.

        Mild depression: to include either situational depression of a limited period or
        depressive symptoms, which do not significantly interfere with the patient's work or daily
        functions.

        Any patient with an active manic element to his/her previous symptom complex will be
        excluded.

        Any known pre-existing medical condition that could interfere with the patient's
        participation in and completion of the study such as:

          -  Pre-existing psychiatric condition, especially severe depression, or a history of
             severe psychiatric disorder

          -  CNS trauma or seizure disorder requiring therapy

          -  Significant cardiac dysfunction in the previous 6 months e.g. angina, CCF,
             hypertension or arrhythmia Patients on treatment are eligible as long as they have
             been symptom free for the previous 6 months.

          -  Poorly controlled diabetes mellitus

          -  Chronic pulmonary disease (e.g. COAD)

          -  Immunologically mediated diseases (e.g. inflammatory bowel disease, SLE, ITP,
             autoimmune hemolytic anemia, scleroderma, rheumatoid arthritis, severe psoriasis)

          -  Clinical gout

          -  Patients with clinically significant retinal abnormalities

          -  Patients with organ transplants

        Any other condition, which in the view of the investigator, would make the patient
        unsuitable for enrolment, or could interfere with the patient participating in and
        completing the protocol are included as well.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nezam H Afdhal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Birmingham Gastroenterology Associates</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UAMS Medical Center</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>34th Street Community Health Center</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93301-1645</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanende-GI Department</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Associates</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Health Sciences Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Danbury Hospital</name>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <zip>06810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bruce Stein, MD</name>
      <address>
        <city>Manchester</city>
        <state>Connecticut</state>
        <zip>06040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connecticut Gastroenterology Consultants</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007-2197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walter Reed Army Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20307-5001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bach and Godofsky Infectious Disease</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Clinical Research Consultants</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Associates of South Florida</name>
      <address>
        <city>S. Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Health Services</name>
      <address>
        <city>Downers Grove</city>
        <state>Illinois</state>
        <zip>60515</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Disease Associates</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lahey Clinic</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hampshire Gastroenterology</name>
      <address>
        <city>Florence</city>
        <state>Massachusetts</state>
        <zip>01062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fallon Clinic</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University/Haper Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Division Veterans Affairs Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Gastroenterology</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55446</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Associates</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA New Jersey Healthcare System</name>
      <address>
        <city>East Orange</city>
        <state>New Jersey</state>
        <zip>07018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Gastroenterology</name>
      <address>
        <city>Egg Harbor</city>
        <state>New Jersey</state>
        <zip>08234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florham Park Endoscopy Center</name>
      <address>
        <city>Florham Park</city>
        <state>New Jersey</state>
        <zip>07932</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern New Mexico Gastroenterology</name>
      <address>
        <city>Santa Fe</city>
        <state>New Mexico</state>
        <zip>87505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Sam Moskowitz, MD, PC</name>
      <address>
        <city>Forest Hills</city>
        <state>New York</state>
        <zip>11375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liberty Medical, LLP</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metro Medical</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter Varunok, MD</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Upstate Medical Center</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guthrie Research Foundation</name>
      <address>
        <city>Sayre</city>
        <state>Pennsylvania</state>
        <zip>18840</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roger Williams Medical Center</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Gastroenterologists</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nashville Gastroenterology Specialists Incorporated</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Gastroenterology</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>G.I. and Liver Associates</name>
      <address>
        <city>Granbury</city>
        <state>Texas</state>
        <zip>76048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Disease Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Transplant Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Science Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2005</verification_date>
  <lastchanged_date>June 23, 2006</lastchanged_date>
  <firstreceived_date>September 10, 2005</firstreceived_date>
  <keyword>hepatitis C</keyword>
  <keyword>cirrhosis</keyword>
  <keyword>interferon</keyword>
  <keyword>colchicine</keyword>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colchicine</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
